Clinical Trials · NCT02333565
Combination of Everolimus and Octreotide LAR in Aggressive Recurrent Meningiomas
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Assistance Publique Hopitaux De Marseille
- Enrollment
- 20
- Start date
- Jan 2015
- Locations
- 1 site, France
- Primary endpoint
- The Progression Free Survival rate